BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10595817)

  • 1. Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia.
    Gladstone DE; Bedi A; Miller CB; Noga SJ; Griffin CA; Piantadosi S; Cagnoni PJ; Brodsky RA; Smith BD; Douglas TT; Shpall EJ; Jones RJ
    Biol Blood Marrow Transplant; 1999; 5(6):394-9. PubMed ID: 10595817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.
    Hájek R; Zácková D; Büchler T; Penka M; Krahulcová E; Korístek Z; Vinklárková J; Adler J; Janovská E; Indrák K; Faber E; Doubek M; Klabusay M; Oltová A; Kuglík P; Bourková L; Dusek L; Mareschová I; Mayer J; Vorlícek J
    Med Oncol; 2003; 20(1):69-76. PubMed ID: 12665687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
    Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
    Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
    Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
    Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML.
    McGlave P; Bhatia R; Verfaillie C
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S65-6. PubMed ID: 8769706
    [No Abstract]   [Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
    Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
    Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
    Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
    Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation.
    Jones RJ; Bedi A
    Curr Opin Oncol; 1994 Mar; 6(2):122-6. PubMed ID: 8011689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
    Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
    Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
    Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
    Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
    Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
    Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.